- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Greenwich LifeSciences gains UK approval for breast cancer trial | 1 | Investing.com | ||
| Mi | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom | 170 | GlobeNewswire (Europe) | STAFFORD, Texas, July 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| GREENWICH LIFESCIENCES Aktie jetzt für 0€ handeln | |||||
| 20.07. | Greenwich LifeSciences: Aktie erholt sich nach detailliertem Update zur FLAMINGO-01-Studie | 1 | Investing.com Deutsch | ||
| 20.07. | Greenwich LifeSciences passt Studiendesign für Brustkrebs-Vakzin an - Aktie bricht ein | 2 | Investing.com Deutsch | ||
| 20.07. | Greenwich LifeSciences updates phase III breast cancer trial design | 2 | Investing.com | ||
| 20.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01 | 434 | GlobeNewswire (Europe) | STAFFORD, Texas, July 20, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 16.07. | Greenwich LifeSciences expands trial enrollment in Europe | 2 | Investing.com | ||
| 16.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 | 173 | GlobeNewswire (Europe) | STAFFORD, Texas, July 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 09.07. | EMA-Zulassung für GP2 beflügelt Aktie von Greenwich LifeSciences | 1 | Investing.com Deutsch | ||
| 09.07. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 | 455 | GlobeNewswire (Europe) | STAFFORD, Texas, July 09, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 04.06. | Greenwich LifeSciences, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.06. | Greenwich LifeSciences, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 01.06. | Greenwich LifeSciences presents immune response data at ASCO | 1 | Investing.com | ||
| 01.06. | Greenwich LifeSciences delays 10-K filing, cites audit coordination | 1 | Investing.com | ||
| 01.06. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Provides Update Regarding Form 10-K Filing | 236 | GlobeNewswire (Europe) | STAFFORD, Texas, June 01, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,... ► Artikel lesen | |
| 22.05. | Greenwich LifeSciences receives Nasdaq noncompliance notice | 1 | Investing.com | ||
| 22.05. | NASDAQ rügt Greenwich LifeSciences wegen Nichteinhaltung von Berichtspflichten | 3 | Investing.com Deutsch | ||
| 22.05. | Greenwich LifeSciences receives Nasdaq notice regarding late Form 10-Q filing | 1 | Seeking Alpha | ||
| 22.05. | Greenwich LifeSciences, Inc.: Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing | 267 | GlobeNewswire (Europe) | STAFFORD, Texas, May 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) ("Greenwich" or the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical... ► Artikel lesen | |
| 30.04. | Greenwich LifeSciences verschiebt Vorlage des Jahresberichts | 1 | Investing.com Deutsch |
1 2 3 Weiter >>
55 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,50 | +0,06 % | BioNTech SE: BioNTech veröffentlicht am 4. August 2026 Ergebnisse für das zweite Quartal 2026 und informiert über operativen Fortschritt | MAINZ, Deutschland, 21. Juli 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, "BioNTech" oder "das Unternehmen") wird am Dienstag, den 4. August 2026, die Ergebnisse für das zweite Quartal 2026 veröffentlichen.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,847 | -0,94 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,200 | -4,89 % | Viking Therapeutics Q2 2026 Earnings Preview | ||
| INFLARX | 1,471 | -1,34 % | InflaRx NV: Die Lage spitzt sich zu: Warum erfahrene Anleger heute die Reißleine ziehen - Die drei Punkte, auf die es jetzt ankommt | ||
| INTELLIA THERAPEUTICS | 9,140 | -2,77 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema | Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published... ► Artikel lesen | |
| KUROS BIOSCIENCES | 21,800 | -1,09 % | Was Insider bei Kuros Biosciences heute bereits wissen: Das Momentum spricht eine klare Sprache - Das sollten Sie jetzt wissen | ||
| ABIVAX | 108,80 | -2,94 % | EQS-News: ABIVAX: Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments | EQS-News: ABIVAX
/ Key word(s): Personnel
Abivax Strengthens Commercial Capabilities With Strategic Leadership Appointments
23.07.2026 / 22:05 CET/CEST
The issuer is... ► Artikel lesen | |
| IBIO | 1,258 | -2,10 % | iBio, Inc.: iBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP Study | Single-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove... ► Artikel lesen | |
| IMMUNITYBIO | 5,990 | -2,60 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| IMMATICS | 7,490 | -3,04 % | Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026 | Houston, Texas and Tuebingen, Germany, July 17, 2026 - Immatics N.V. (NASDAQ: IMTX, "Immatics" or the "Company"), the global leader in precision targeting of PRAME with multiple clinical-stage programs... ► Artikel lesen | |
| MANNKIND | 3,533 | +1,58 % | MannKind Announces $50 Million Private Placement | DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,699 | -5,03 % | Cardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| IMMUNIC | 11,365 | -6,19 % | EQS-News: Immunic AG: Immunic to Participate in Investor Conferences in July | Issuer: Immunic AG
/ Key word(s): Conference
Immunic to Participate in Investor Conferences in July
09.07.2026 / 12:30 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 4,160 | -3,37 % | Iovance Biotherapeutics, Inc.: Iovance's Amtagvi (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia | First T cell therapy for a solid tumor cancer and first treatment option approved in Australia for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., June 03, 2026 (GLOBE... ► Artikel lesen | |
| ARGENX | 771,20 | -2,16 % | DEUTSCHE BANK RESEARCH stuft Argenx auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Argenx nach einem Expertengespräch zur Skeletterkrankung Myositis auf "Buy" mit einem Kursziel von 900 Euro belassen. Die... ► Artikel lesen |
Das Unternehmen GREENWICH LIFESCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,520 (+4,01 %) liegt der Kurs bei 13,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GREENWICH LIFESCIENCES INC finden Sie auf Wallstreet Online.